EGFR and non-small cell lung carcinoma: The ADAURA trial was conducted as a randomized phase III study comparing osimertinib, a third-generation EGFR-TKI, with a placebo as adjuvant therapy in patients with stages IB–IIIA EGFR mutant NSCLC.